



1-MINUTE CONSULT

Dushyant Singh Dahiya, MD

Department of Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI

Asim Kichloo, MD, FACP

Associate Professor, Department of Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI; Program Director, Department of Internal Medicine, Samaritan Medical Center, Watertown, NY

BRIEF
ANSWERS
TO SPECIFIC
CLINICAL
QUESTIONS

Rawan Amir, MD

Department of Internal Medicine, University of Maryland Medical Center, Baltimore, MD

Farah Wani, MD

Department of Family Medicine, Samaritan Medical Center, Watertown, NY

Q: When should antithrombotic therapy be resumed after gastrointestinal bleeding?

A: RESTARTING ANTITHROMBOTIC THERAPY is recommended when indicated in patients after gastrointestinal bleeding, such as those with acute coronary syndromes or atrial fibrillation, or following percutaneous intervention.¹ However, the timing is critical, as premature re-initiation can lead to recurrent bleeding, and delayed re-initiation can increase risk of thromboembolic events.

Antithrombotic therapy decreases unfavorable outcomes secondary to underlying etiology.¹ The timing of re-initiating therapy after gastrointestinal bleeding warrants an individualized approach. The plan may be modified after consideration of factors related to the bleeding event, thromboembolic risk, and patient comorbidities.¹

MAGNITUDE OF THE PROBLEM

In the United States, antiplatelet and oral anticoagulant (OAC) therapy has increased considerably, from 29.5% in 2011 to 68.0% in 2017 with a sizeable contribution from increased use of novel OACs (non-vitamin K OACs) from 0.1% in 2011 to 43.5% in 2017.² Antiplatelet use has also increased, but use of clopidogrel decreased from 100% to 65% by the end of 2011 and leveled off thereafter.³ In 2013, clopidogrel still remained the most prescribed OAC, and ticagrelor had replaced a substantial portion of prasugrel.³ Use of the combination of an OAC and single antiplatelet drug (dual therapy) increased from 14.8% in 2011 to 36.3% in 2017, and use of an OAC with dual antiplatelet therapy (triple therapy) increased from 14.6% in 2011 to 31.6% in 2017.²

Bleeding commonly complicates antithrombotic

therapy. The reported incidence of bleeding associated with OAC therapy varies from 10 to 17 and 2 to 5 per 100 patient years for all bleeding complications and for major bleeding complications, respectively, depending on patient characteristics and underlying diseases.^{1,4-6} Numerous trials—eg, Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH),⁷ Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA),⁸ and Secondary Prevention of Small Subcortical Strokes Trial (SPS3)⁹ have shown increased risk of early bleeding with dual antiplatelet therapy compared with either separate regimen.¹⁰ Furthermore, triple therapy is associated with higher bleeding risk compared with dual therapy despite similar rates of all-cause mortality.¹¹

RISKS AND BENEFITS OF RESTARTING THERAPY

Although resumption of anticoagulant therapy after gastrointestinal bleeding is associated with increased risk of recurrent bleeding, it is also associated with significant decrease in thromboembolic events and all-cause mortality.¹² A number of clinical trials^{7,8,13-15} have compared agents for ideal therapy. The WOEST trial (What Is the Optimal Antiplatelet and Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary Stenting?)^{13,14} reported that dual therapy caused fewer bleeding events than triple therapy, with no excess ischemic events or trade-off in efficacy.

Among OACs, novel OACs were associated with fewer bleeding events compared with vitamin K antagonists (eg, warfarin, acenocoumarol) and were as effective; hence, direct-acting OACs (eg, apixaban, dabigatran, edoxaban, rivaroxaban) are the preferred

doi:10.3949/ccjm.89a.20189

agents.¹³ Furthermore, current evidence also favors re-initiating antithrombotic therapy after gastrointestinal bleeding as it leads to better mortality outcomes.¹⁶ Of the P2Y₁₂ receptor inhibitors commonly used (clopidogrel, ticlopidine, ticagrelor, prasugrel, and cangrelor), clopidogrel is preferred as it is effective and has the lowest bleeding risk, followed by ticagrelor.¹³

■ TOOLS FOR DECISION-MAKING

The HAS-BLED scoring is a useful tool that has been validated for predicting bleeding risk in patients who require OACs, particularly those with atrial fibrillation or flutter.¹⁷ Points are given for hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio (INR), age over 65, use of medications that predispose to bleeding, and consumption of alcohol. A score of 3 or higher indicates a high risk of bleeding ($\geq 5.8\%$ per year).¹³ Other scoring systems (eg, Glasgow-Blatchford,¹⁸ Rockall¹⁹) are available and may guide decision-making in specific situations.

■ TRIVIAL AND MILD BLEEDING

For trivial bleeding, antithrombotic therapy may be continued without interruption.^{20–22} For patients with mild bleeding (needing medical attention without hospital stay), dual antiplatelet therapy may be continued, but re-evaluation of the duration of therapy or switching from a stronger (eg, ticagrelor or prasugrel) to a weaker agent (clopidogrel) should be considered.^{20–22} For patients on triple therapy, de-escalating to dual therapy may be considered.^{13,20} Patients on vitamin K antagonists may be advised to postpone the next dose until the INR is less than 2.^{21,23,24} Patients on novel OAC therapy may be asked to skip one dose.²⁰

■ MODERATE BLEEDING

Moderate bleeding is defined by a hemoglobin drop of 3.2 g/dL or bleeding that requires hospitalization in a patient who is otherwise hemodynamically stable.^{21,22} For moderate bleeding, interrupting dual antiplatelet therapy and switching to a single agent, preferably a P2Y₁₂ inhibitor (eg, clopidogrel, ticagrelor) is recommended, especially in upper gastrointestinal bleeding.^{20,21,25} Dual antiplatelet therapy may be re-initiated within 3 days after gastrointestinal bleeding has stopped, but the duration of therapy may be shortened, and switching from a stronger to a weaker agent should be considered.^{20,21,25}

If using OACs, therapy should be discontinued

and vitamin K antagonists therapy should be reversed until gastrointestinal bleeding stops, unless very high thromboembolic risk is present: eg, mechanical heart valve, cardiac assist device, or a CHA₂DS₂-VASc (congestive heart failure, hypertension, age ≥ 75 , diabetes mellitus, stroke/transient ischemic attack–vascular disease, age 65–74, female sex) score of 4 or higher.^{21–23} In patients on dabigatran, activated charcoal may be used if the last dose of novel OAC is within 2 to 4 hours.²¹ OAC therapy should be re-initiated within 1 week of gastrointestinal bleeding with a direct-acting OAC at the minimum possible dose, or with a vitamin K antagonist with a target INR of 2 to 2.5.^{20,21} If the patient was on triple therapy, de-escalate to dual therapy.^{13,20–22}

■ SEVERE BLEEDING

Severe bleeding is characterized by more than a 4.8-g/dL drop in hemoglobin requiring hospitalization in a patient otherwise hemodynamically stable.²¹ In these patients, all recommendations stated for moderate bleeding may apply; however, all antithrombotic medications should be discontinued if bleeding persists despite treatment.^{20,21} The need for antiplatelets should be re-evaluated. If needed, the duration of therapy should be shortened and a weaker agent used.^{21,22}

If the patient was on OACs, stopping and reversing therapy is indicated unless there is a high risk of thromboembolic events.^{21,22} The preferred reversal agent for vitamin K antagonists is a prothrombin complex concentrate.^{21,23,26,27} Additionally, the guideline recommends against the use of prothrombin complex concentrates for novel OAC reversal (very low certainty of evidence).^{21,26,27} In patients on dabigatran, reversal may be done with idarucizumab, which acts in under 5 minutes.^{20–24,28}

Therapy with OACs should be re-initiated, only if indicated, within 1 week of gastrointestinal bleeding, with a direct-acting OAC starting at the minimum dose or a vitamin K antagonist with a target INR of 2 to 2.5.^{20–22} If the patient was on triple therapy, de-escalating to dual therapy may be considered.^{13,20,21} If the patient is on dual therapy, consider discontinuation if safe.^{20,21}

■ LIFE-THREATENING BLEEDING

In cases of life-threatening bleeding, all antithrombotic therapy should be discontinued immediately.^{20,21} If using OAC therapy, discontinue and reverse immediately.^{20,21} Re-initiation of antiplatelets in life-threatening bleeding requires additional evaluation with endoscopy and assessment of patient risk factors.^{20–22,24}

If a decision is made to restart antiplatelet therapy, a P2Y12 inhibitor should be used, especially in upper gastrointestinal bleeding. If restarting OAC therapy, low-dose apixaban is preferred.²⁰

TAKE-HOME MESSAGES

- Use an individualized approach to re-initiate anti-thrombotic therapy after gastrointestinal bleeding.
- For trivial and mild bleeding, an OAC and anti-platelet drug may be continued with adjustments in the regimen.
- When using antiplatelets for moderate or severe bleeding, periodically re-evaluate the need for these agents. If indicated, re-initiate within 3 days after gastrointestinal bleeding has stopped. However, the duration of therapy may be shortened, and switching from a stronger to weaker agent should be considered. Dual antiplatelet therapy may be switched to a single agent, preferably a

P2Y12 inhibitor.

- When using OAC drugs for moderate or severe bleeding, therapy should be re-initiated within 1 week of gastrointestinal bleeding with a direct-acting OAC, starting at the minimum dose, and with vitamin K antagonists with a target INR of 2 to 2.5. If the patient was on triple therapy, de-escalate to dual therapy.
- For life-threatening bleeding, all therapy should be stopped immediately and reversed. After endoscopic evaluation and assessment of patient risk factors, if a decision is made to re-initiate therapy with an OAC, low-dose apixaban is preferred. If restarting antiplatelet therapy, a P2Y12 inhibitor is preferred.

DISCLOSURES

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

REFERENCES

1. Witt DM. What to do after the bleed: resuming anticoagulation after major bleeding. *Hematology Am Soc Hematol Educ Program* 2016; 2016(1):620–624. doi:10.1182/asheducation-2016.1.620
2. Batra G, Lindhagen L, Hijazi Z, et al. Trends in use of oral anti-thrombotic agents in patients with atrial fibrillation and myocardial infarction. *J Am Coll Cardiol* 2020; 75(11 suppl 1):159. doi:10.1016/S0735-1009(20)30786-5
3. Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardatti AK, Walton SM. Contemporary trends in oral antiplatelet agent use in patients treated with percutaneous coronary intervention for acute coronary syndrome. *J Manag Care Spec Pharm* 2017; 23(1):57–63. doi:10.18553/jmcp.2017.23.1.57
4. Rubboli A, Becattini C, Verheugt FW. Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. *World J Cardiol* 2011; 3(11):351–358. doi:10.4330/wjc.v3.i11.351
5. Kuijter PMM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. *Arch Intern Med* 1999; 159(5):457–460. doi:10.1001/archinte.159.5.457
6. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). *Italian Study on Complications of Oral Anticoagulant Therapy*. *Lancet* 1996; 348(9025):423–428. doi:10.1016/S0140-6736(96)01109-9
7. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet* 2004; 364(9431):331–337. doi:10.1016/S0140-6736(04)16721-4
8. Berger JS, Bhatt DL, Steg PG, et al. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. *Am Heart J* 2011; 162(1): 98–105.e1. doi:10.1016/j.ahj.2011.04.015
9. SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. *N Engl J Med* 2012; 367(9):817–825. doi:10.1056/NEJMoa1204133
10. Hilken NA, Algra A, Kappelle LJ, et al. Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke. *Neurology* 2018; 90(8):e683–e689. doi:10.1212/WNL.0000000000004997
11. Dahal K, Mustafa U, Sharma SP, et al. Ischemic and bleeding outcomes of triple therapy in patients on chronic anticoagulation undergoing percutaneous coronary intervention: a meta-analysis of randomized trials. *JRSM Cardiovasc Dis* 2019; 8:2048004019885572. doi:10.1177/2048004019885572
12. Tapaskar N, Pang A, Werner DA, Sengupta N. Resuming anticoagulation following hospitalization for gastrointestinal bleeding is associated with reduced thromboembolic events and improved mortality: results from a systematic review and meta-analysis. *Dig Dis Sci* 2021; 66(2):554–566. doi:10.1007/s10620-020-06248-9
13. Kichloo A, Aljadah MM, Wani F, Ananthaneni S. Should we give triple therapy to patients with atrial fibrillation after percutaneous intervention? *Cleve Clin J Med* 2020; 87(10):599–601. doi:10.3949/ccjm.87a.19115
14. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. *Lancet* 2013; 381(9872):1107–1115. doi:10.1016/S0140-6736(12)62177-1
15. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. *N Engl J Med* 2019; 380(16):1509–1524. doi:10.1056/NEJMoa1817083
16. Bingzheng X, Jingnan R, Ligang B, Jianping C. The effects of anticoagulant therapy re-initiation after gastrointestinal bleeding: a systematic review and meta-analysis. *J Clin Pharm Ther* 2021; 46(6):1509–1518. doi: 10.1111/jcpt.13442
17. Pisters R, Lane DA, Nieuwlaar R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010; 138(5):1093–1100. doi:10.1378/chest.10-0134
18. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. *Lancet* 2000; 356(9238):1318–1321. doi:10.1016/S0140-6736(00)02816-6
19. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. *Gut* 1996; 38(3): 316–321. doi:10.1136/gut.38.3.316
20. Gimbel ME, Minderhoud SCS, Ten Berg JM. A practical guide on how to handle patients with bleeding events while on oral

- antithrombotic treatment. *Neth Heart J* 2018; 26(6):341–351. doi:10.1007/s12471-018-1117-1
21. **Abraham NS, Barkun AN, Sauer BG, et al.** American College of Gastroenterology–Canadian Association of Gastroenterology clinical practice guideline: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period. *Am J Gastroenterol* 2022; 117(4):542–558. doi:10.14309/ajg.0000000000001627
 22. **Valgimigli M, Bueno H, Byrne RA, et al.** 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2017; 39(3):213–260. doi:10.1093/eurheartj/ehx419
 23. **Kirchhof P, Benussi S, Kotecha D, et al.** 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016; 37(38):2893–2962. doi:10.1016/j.rec.2016.11.033
 24. **Heidbuchel H, Verhamme P, Alings M, et al.** Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. *Europace* 2015; 17(10):1467–1507. doi:10.1093/europace/euv309
 25. **Halvorsen S, Storey RF, Rocca B, et al.** Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. *Eur Heart J* 2017; 38(19):1455–1462. doi:10.1093/eurheartj/ehw454
 26. **Dentali F, Marchesi C, Giorgi Pierfranceschi M, et al.** Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. *Thromb Haemost* 2011; 106(3):429–438. doi:10.1160/TH11-01-0052
 27. **Majeed A, Eelde A, Agren A, Schulman S, Holmstrom M.** Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. *Thromb Res* 2012; 129(2):146–151. doi:10.1016/j.thromres.2011.07.024
 28. **Niessner A, Tamargo J, Morais J, et al.** Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. *Eur Heart J* 2017; 38(22):1710–1716. doi:10.1093/eurheartj/ehv676

Address: Asim Kichloo, MD, FACP, Department of Internal Medicine, Central Michigan University College of Medicine, 1000 Houghton Avenue, Saginaw, MI 48602; kichlooasim@gmail.com